Gerber Peter Arne, Buhren Bettina A, Bölke Edwin, Philipp-Dormston Wolfgang G, Homey Bernhard, Schrumpf Holger
From the Department of Dermatology, Medical Faculty, University Hospital Duesseldorf.
Dermatologie am Luegplatz.
Plast Reconstr Surg. 2023 Mar 1;151(3):560-567. doi: 10.1097/PRS.0000000000009916. Epub 2022 Nov 22.
Hyaluronidase (HYAL) is regarded as the standard for the management of complications associated with hyaluronan (HA)-based fillers. Therefore, the understanding of interactions of HA fillers and HYAL is essential.
Nine different commercially available HA fillers (Belotero, Juvéderm, and Restylane) with varying degrees of cross-linking were used for the analysis. Fluorescently dyed HA fillers were individually incubated with varying doses of HYAL [bovine HYAL (Hylase "Dessau"; Riemser Pharma, Germany); 5, 10, and 20 U/mL] or sodium chloride and monitored by time-lapse microscopy. HA filler degradation was assessed as a decrease in fluorescence intensity of HA filler plus HYAL compared to HA filler plus control, quantified by computerized image analysis.
HA fillers show significant differences in their reaction to HYAL. Levels of degradation of HA fillers are positively correlated with increasing concentrations of HYAL. At the highest concentration of HYAL (20 U/mL), all fillers except one (Belotero Volume) reached a significant level of degradation at 5 to 9 hours.
In this study, the authors show that most HA fillers can be dissolved by HYAL in a dose- and time-dependent manner. Of note, the fillers' technology and degree of cross-linking seem to exert stronger effects on the degradability by HYAL as compared to the concentration of HA.
The authors' in vitro analyses support clinical recommendations stating that in the case of a vascular filler incident, HYAL should be applied early and at significant doses ("Time is skin!").
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, V.
透明质酸酶(HYAL)被视为处理与透明质酸(HA)填充剂相关并发症的标准方法。因此,了解HA填充剂与HYAL的相互作用至关重要。
使用九种不同的市售HA填充剂(贝洛特罗、乔雅登和瑞蓝),其交联程度各不相同,用于分析。将荧光染色的HA填充剂分别与不同剂量的HYAL[牛HYAL(德绍透明质酸酶;德国里姆瑟制药公司);5、10和20 U/mL]或氯化钠一起孵育,并通过延时显微镜进行监测。通过计算机图像分析对HA填充剂降解进行评估,即与HA填充剂加对照相比,HA填充剂加HYAL的荧光强度降低。
HA填充剂对HYAL的反应存在显著差异。HA填充剂的降解水平与HYAL浓度增加呈正相关。在HYAL的最高浓度(20 U/mL)下,除一种填充剂(贝洛特罗Volum)外,所有填充剂在5至9小时时均达到显著降解水平。
在本研究中,作者表明大多数HA填充剂可被HYAL以剂量和时间依赖性方式溶解。值得注意的是,与HA浓度相比,填充剂的技术和交联程度似乎对HYAL的降解能力影响更大。
作者的体外分析支持临床建议,即在发生血管填充剂相关事件时,应尽早且大剂量应用HYAL(“时间就是皮肤!”)。
临床问题/证据水平:治疗性,V级